Summit Therapeutics Share Discussion Threads

[chrisatrdg] 12/11/2018 10:35

Per Bloomberg:

Company Overview

'Bryan, Garnier & Co. GmbH is an investment bank that specializes in European growth companies. The company caters to corporations, venture capitalists, institutional investors, and private clients through asset management, corporate finance, sales, and trading. The company’s corporate finance practice includes private equity placements, initial public offerings, and mergers and acquisitions. It research department covers telecommunications, technology, media, pharmaceuticals, consumer goods, luxury goods, and outsourcing services. Bryan, Garnier & Co. GmbH is based in Munich, Germany with additional offices in London, United Kingdom; Paris, France; and Geneva, Switzerland.'

[chrisatrdg] 12/11/2018 10:02

We are not the only ones:

ImmuPharma PLC Appoints Bryan Garnier as Joint Broker:



Interesting I think.

Edit: Another interesting link:

Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner for MedinCell’s €30 million Euronext Paris IPO

News published on October Monday 8, 2018:



Edit: It looks to me that these new joint brokers are big hitters I think something is being developed to move Summit on.

[phowdo] 12/11/2018 08:46

A placing and/or they need to drum up some interest to clear out the funds that are selling out. Perhaps time for Glyn to step aside and let a younger more dynamic CEO take the reins.

[lagosboy] 12/11/2018 08:36

My money on a Placing - bad sign they need additional cost of another broker to help get it away.

[chrisatrdg] 12/11/2018 08:11

Per jimbobtechstock from the other board:

'Either that or some other deal including stock. They have cash already and Bryan Garnier is not an AIM fodder placing broker so I suspect whatever is being lined up is a longer-term funding deal related to getting the phIII underway somehow. No idea what sort of arrangement tho'

[nobbygnome] 12/11/2018 07:49

Good point. Let's hope that is true although I doubt it will happen. More than happy to be proved wrong....

[multiplural] 12/11/2018 07:48

It could also mean a sales process is on its way :-)

[chrisatrdg] 12/11/2018 07:14

Nobbygnome - I hope not things are bad enough without a fund raise to add further dilution but would anyone go for it as it would solve the funding issue?

[nobbygnome] 12/11/2018 07:11

Usually a fund raising is coming.....😣

[multiplural] 11/11/2018 09:59

I think the company should be put on the block. I guess we could achieve at least 60p per share in a sale.

[nobbygnome] 11/11/2018 07:51

Yes a very small holding by my standards.

It was bought on the basis that waterloo can't always be wrong. However, so far it seems he can 😜.....

[kirk 6] 10/11/2018 20:26

Yes but up £130k last week on upgs and not selling any summ or imm till a profit if at all. Didn't you buy in here at 34p ish?

[nobbygnome] 10/11/2018 19:35

>> kirk

So massively down on IMM and SUMM....

[lagosboy] 10/11/2018 18:28

In your dreams

[kirk 6] 10/11/2018 16:21

Are you sure? I've got just under 1m of these at around 35p and buying more when I free funds.Director bought at 38.5p only recently Source: UK Regulatory (RNS & others) TIDMSUMM Summit Therapeutics plc ("Summit", the "Company", or the "Group") Director / PDMR Share Dealing Oxford, UK, Cambridge, MA, US, 16 July - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), announces that it was notified on 13 July 2018 that Glyn Edwards, Summit's Chief Executive Officer, purchased 150,000 ordinary shares of 1p each in the Company at 38 pence per share.

[lagosboy] 10/11/2018 11:25

If true- lucky Glyn with all his options !

Summ has no correlation to n4p whatsoever - you may as well pick any pharma that just happened to rise last week.

Try the one year look - 32 p to 12 p

Another blatant ramp - £26k to invest - having a laugh, stop trying to mis-lead good honest folk.

[kirk 6] 10/11/2018 08:57

Look at n4p recently this will do the same. Adding another 100k shares next week

[multibagger] 10/11/2018 05:58

The latest MIT Technology Review: Vol 121 No.6 Nov/Dec 2018 - "The Precision Medicine Issue" makes fascinating reading for anyone with an interest in healthcare trends.

Could well inform investing decisions too :)

[kirk 6] 09/11/2018 21:36

Nope I trade quite a few stocks on the Nasdaq below 1 dollar. Traded SMMT before aswell

[football] 09/11/2018 20:12

if we go below a dollar do we get kick off the NASDAQ ?

[lagosboy] 09/11/2018 17:33

Apart from in very rare circumstances the days of buying companies for a discount of the value of their tax losses are now days of the past.

In simple terms if the buyer is to gain any benefit from the tax losses, it must be sufficiently confident that the target business can recover.

Probably of more concern is that without a capital reorganisation which will crucify existing shareholders, dividends cannot be paid until the deficit on the P/L or accumulated losses are cleared.

Unfortunately Mr Edwards in order to keep control, issue share awards on an industrial scale and waste money attending every conference on the planet has missed a golden opportunity to raise meaningful funding - an opportunity I doubt will ever return.

[waterloo01] 09/11/2018 15:15

Was £115m as at last accounts, but will be large write down in the next ones re DMD.

[multiplural] 09/11/2018 15:08

Does anyone know how much tax loss carry forward Summit have ?

[lagosboy] 08/11/2018 15:04

But not at the rate the CEO spends it - here today, gone tomorrow.

You can never be fairly certain the science is good with any pharma- and in many ways if that were true the situation would be more worrying because it would have attracted more interest than it has to date.

Its time for a new CEO - Glyn's got a pretty hopeless track record and appears to excel in looking after himself as evidenced by the last shed load of share options awarded.

How many times does he have to disappoint ?